EMG
FOLD

Ellington Management Group’s Amicus Therapeutics FOLD Stock Holding History

Ellington Management Group’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-10,400
Closed -$96K – 179
2020
Q1 		$96K Buy
+10,400
New +$98.9K 0.02% 495
2019
Q1 		– Sell
-10,200
Closed -$98K – 603
2018
Q4 		$98K Buy
+10,200
New +$112K 0.03% 352
2018
Q3 		– Sell
-45,900
Closed -$717K – 563
2018
Q2 		$717K Buy
+45,900
New +$694K 0.05% 123
2016
Q3 		– Sell
-21,000
Closed -$115K – 651
2016
Q2 		$115K Buy
+21,000
New +$147K 0.16% 208
2014
Q4 		– Sell
-15,200
Closed -$90K – 582
2014
Q3 		$90K Buy
+15,200
New +$79.6K 0.06% 273

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ellington Management Group's FOLD Position: Q2 2020 in Review

Ellington Management Group sold out of Amicus Therapeutics (FOLD) in Q2 2020, closing a stake of 10,400 shares — an estimated $96K sold.

Ellington Management Group first reported a position in FOLD in Q3 2014 and held it in 5 quarters. The position peaked at $717K in Q2 2018. 226 funds tracked by Wall St. Rank hold FOLD as of Q2 2020.

  • Ellington Management Group reported no remaining Amicus Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Ellington Management Group sold 10,400 Amicus Therapeutics shares in Q2 2020, an estimated $96K.
  • Ellington Management Group first reported a position in Amicus Therapeutics in Q3 2014 and held it in 5 quarters.
  • Ellington Management Group's Amicus Therapeutics position peaked at $717K in Q2 2018.
  • 226 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2020.

Based on Ellington Management Group's 13F filing for Q2 2020, filed 17 Aug 2020.